ATE365214T1 - Ligand des zelleintritt-vermittelnden proteins von herpes simplex und methoden zu dessen verwendungen - Google Patents

Ligand des zelleintritt-vermittelnden proteins von herpes simplex und methoden zu dessen verwendungen

Info

Publication number
ATE365214T1
ATE365214T1 AT01926879T AT01926879T ATE365214T1 AT E365214 T1 ATE365214 T1 AT E365214T1 AT 01926879 T AT01926879 T AT 01926879T AT 01926879 T AT01926879 T AT 01926879T AT E365214 T1 ATE365214 T1 AT E365214T1
Authority
AT
Austria
Prior art keywords
methods
herpes simplex
herpes virus
cell entry
protein ligand
Prior art date
Application number
AT01926879T
Other languages
English (en)
Inventor
Carl Ware
Original Assignee
Jolla Inst Allergy Immunolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jolla Inst Allergy Immunolog filed Critical Jolla Inst Allergy Immunolog
Application granted granted Critical
Publication of ATE365214T1 publication Critical patent/ATE365214T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
AT01926879T 2000-04-12 2001-04-11 Ligand des zelleintritt-vermittelnden proteins von herpes simplex und methoden zu dessen verwendungen ATE365214T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54909600A 2000-04-12 2000-04-12

Publications (1)

Publication Number Publication Date
ATE365214T1 true ATE365214T1 (de) 2007-07-15

Family

ID=24191643

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05023967T ATE483807T1 (de) 2000-04-12 2001-04-11 Ligand des zelleintritt-vermittelnden proteins von herpes simplex und methoden zu dessen verwendungen
AT01926879T ATE365214T1 (de) 2000-04-12 2001-04-11 Ligand des zelleintritt-vermittelnden proteins von herpes simplex und methoden zu dessen verwendungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT05023967T ATE483807T1 (de) 2000-04-12 2001-04-11 Ligand des zelleintritt-vermittelnden proteins von herpes simplex und methoden zu dessen verwendungen

Country Status (10)

Country Link
EP (2) EP1674575B1 (de)
JP (1) JP2003531152A (de)
AT (2) ATE483807T1 (de)
AU (1) AU5338701A (de)
CA (1) CA2406132C (de)
CY (1) CY1111293T1 (de)
DE (2) DE60143231D1 (de)
DK (1) DK1674575T3 (de)
ES (1) ES2352742T3 (de)
PT (1) PT1674575E (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007010692A1 (ja) * 2005-07-19 2007-01-25 Japan Science And Technology Agency Ｈｖｅｍ及びｂｔｌａを標的とした炎症性腸疾患治療用医薬組成物及び治療方法
WO2010051502A2 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
GB201701194D0 (en) 2017-01-24 2017-03-08 Capella Bioscience Ltd Antigen binding molecules that bind light
US11312781B2 (en) 2018-01-24 2022-04-26 Capella Bioscience Ltd. Antigen binding molecules that bind LIGHT
WO2021202649A2 (en) 2020-04-01 2021-10-07 Aevi Genomic Medicine, Llc Methods and treatment involving excess free light
CN111991551A (zh) * 2020-07-31 2020-11-27 中国人民解放军海军军医大学 Traf3半胱氨酸突变体在制备抗病毒药物中的应用
US20240317871A1 (en) * 2020-12-30 2024-09-26 Immunomic Therapeutics, Inc. Anti-HVEM Antibodies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
US6479254B2 (en) * 1996-03-22 2002-11-12 Human Genome Sciences, Inc. Apoptosis inducing molecule II
CA2248868A1 (en) * 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
DE69730607T2 (de) * 1996-07-19 2005-01-27 Takeda Chemical Industries, Ltd. Fas ligand ähnliches protein, seine herstellung und verwendung
KR100584704B1 (ko) * 1996-10-25 2006-05-30 바이오겐 아이덱 엠에이 인코포레이티드 면역 질환을 치료하기 위한 치료제로서의 가용성 림포톡신-베타 수용체, 항림포톡신 수용체 항체 및 항림포톡신 리간드 항체
CA2270913C (en) * 1996-10-30 2011-05-24 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like 2
WO1998025967A1 (en) * 1996-12-12 1998-06-18 Genentech, Inc. Hvem polypeptides and uses thereof
JP2001524985A (ja) * 1997-05-12 2001-12-04 スミスクライン・ビーチャム・コーポレイション ヒト腫瘍壊死因子受容体様２（ｔｒ２）抗体
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6346388B1 (en) * 1997-08-13 2002-02-12 Smithkline Beecham Corporation Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
WO1999011662A1 (en) * 1997-09-05 1999-03-11 Millennium Biotherapeutics, Inc. Novel molecules of the tnfr-ligand-related protein family and uses thereof
AU2972199A (en) * 1998-02-20 1999-09-06 Reinhard Ebner Apoptosis inducing molecule ii and methods of use
AU5568799A (en) * 1998-08-18 2000-03-14 Northwestern University Peptides for inhibition of herpes simplex virus entry
AU5804499A (en) * 1998-09-03 2000-03-27 Millennium Pharmaceuticals, Inc. Novel molecules of the herpes virus-entry-mediator-related protein family and uses thereof
CZ20011272A3 (cs) * 1998-10-09 2001-09-12 Biogen, Inc. Použití činidla, které blokuje vazbu lymfotoxinu-beta na jeho receptor, pro výrobu protivirového léku
AU3623700A (en) * 1999-03-11 2000-09-28 Reinhard Ebner Apoptosis inducing molecule ii and methods of use

Also Published As

Publication number Publication date
CY1111293T1 (el) 2015-08-05
DE60129010D1 (de) 2007-08-02
EP1674575B1 (de) 2010-10-06
CA2406132A1 (en) 2001-10-25
DE60143231D1 (de) 2010-11-18
PT1674575E (pt) 2010-12-06
ATE483807T1 (de) 2010-10-15
EP1674575A2 (de) 2006-06-28
DE60129010T2 (de) 2008-02-28
DK1674575T3 (da) 2010-11-29
EP1274840B1 (de) 2007-06-20
EP1274840A2 (de) 2003-01-15
JP2003531152A (ja) 2003-10-21
ES2352742T3 (es) 2011-02-22
CA2406132C (en) 2012-07-03
AU5338701A (en) 2001-10-30
EP1674575A3 (de) 2007-08-08

Similar Documents

Publication Publication Date Title
ATE495240T1 (de) Ligand des zelleintritt-vermittelnden proteins von herpes simplex virus und methoden zu dessen verwendung
ATE461938T1 (de) Mit entzündlichen darmerkrankungen (ibd) assoziierte mikrobielle antigene und verfahren derer anwendung
CY1111293T1 (el) Συνδετης για μεσολαβητη εισοδου του ιου του απλου ερπητα και μεθοδοι χρησης
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
ATE172984T1 (de) Nukleinsäuren-bindende oligomere mit n- verzweigung für therapie und diagnostik
BR9808934A (pt) Proteìnas de fusão de região constante de receptor/imunoglobulina tgf-beta do tipo ii
ATE403680T1 (de) Herstellung tetravalenter antikörper
ATE280178T1 (de) Langwellig fluorezierende proteine
ATE339507T1 (de) Erythropoietin-analog-menschliches serum-albumin fusionsprotein
ATE315643T1 (de) Cdn apoptosis modulierende proteine, sie kodierende dns und verfahren zu ihrer verwendung
DE60041452D1 (de) CpG REZEPTOR (CpG-R) UND DARAUF BEZOGENE METHODEN
FR2827866B1 (fr) Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations
WO2001079496A3 (en) Ligand for herpes simplex virus entry mediator and methods of use
ATE180494T1 (de) Nukleinsäure-bindende oligomere mit c-verzweigung für therapie und diagnostik
DE69915320D1 (de) Immunoglobulin-bindende proteine
EA200100264A1 (ru) Ангиоцидин: адгезионный рецептор опухолей клетки, специфический для cys-ser-val-thr-cys-gly
DK0981601T3 (da) Fremgangsmåder til dyrkning af celler og opformering af vira
EP1530579A4 (de) Rekombinante antikörper sowie zusammensetzungen und verfahren zu deren herstellung und verwendung
WO1998049333A3 (en) Eukaryotic gene expression cassette and uses thereof
DE69806107D1 (de) Methoden und reagenzien zur regulierung von apoptosis
EP1191096A4 (de) Neues protein und dessen dns
DE59710091D1 (de) Von Kaposi-sarkom assoziiertem Herpes-Virus (KSHV, HHV-8) kodiertes Polypeptid und dessen Verwendung in Diagnostik und Therapie
DE60016183D1 (de) Verfahren zur verwendung von viraler replicase
DE502004003467D1 (de) Von vca-p18 kapsidantigen des epstein-barr-virus abgeleitete peptide und ihre verwendung
NO970130L (no) Oligomere bærermolekyler med definerte, innebygde markörgrupper og haptener

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties